MA45543A - Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées - Google Patents

Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées

Info

Publication number: MA45543A
Authority: MA; Morocco
Prior art keywords: peptides; amyloid beta; beta antibodies; associated uses; n3pglu amyloid
Prior art date: 2016-07-01

Application number

MA045543A

Other languages

English (en)

Other versions

MA45543B1 (fr

Inventor

Ronald Bradley Demattos

Michael Carl Irizarry

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-01

Filing date

2017-06-23

Publication date

2019-05-08

2017-06-23 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2019-05-08 Publication of MA45543A publication Critical patent/MA45543A/fr

2023-08-31 Publication of MA45543B1 publication Critical patent/MA45543B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA45543A 2016-07-01 2017-06-23 Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations MA45543B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662357579P	2016-07-01	2016-07-01
PCT/US2017/038999 WO2018005282A1 (fr)	2016-07-01	2017-06-23	Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées

Publications (2)

Publication Number	Publication Date
MA45543A true MA45543A (fr)	2019-05-08
MA45543B1 MA45543B1 (fr)	2023-08-31

Family

ID=59295341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA45543A MA45543B1 (fr)	2016-07-01	2017-06-23	Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations

Country Status (28)

Country	Link
US (2)	US11312763B2 (fr)
EP (2)	EP3478712B1 (fr)
JP (4)	JP7165588B2 (fr)
KR (3)	KR20230021773A (fr)
CN (3)	CN109415433A (fr)
AU (1)	AU2017291414B2 (fr)
CA (1)	CA3029550C (fr)
DK (1)	DK3478712T5 (fr)
EA (1)	EA201892690A1 (fr)
ES (1)	ES2958508T3 (fr)
FI (1)	FI3478712T3 (fr)
HR (1)	HRP20230861T1 (fr)
HU (1)	HUE062980T2 (fr)
IL (1)	IL263788B2 (fr)
LT (1)	LT3478712T (fr)
MA (1)	MA45543B1 (fr)
MD (1)	MD3478712T2 (fr)
MX (2)	MX2018016066A (fr)
NZ (1)	NZ772768A (fr)
PL (1)	PL3478712T3 (fr)
PT (1)	PT3478712T (fr)
RS (1)	RS64386B1 (fr)
SG (1)	SG11201810371XA (fr)
SI (1)	SI3478712T1 (fr)
TW (2)	TWI735600B (fr)
UA (2)	UA127101C2 (fr)
WO (1)	WO2018005282A1 (fr)
ZA (1)	ZA201807633B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
TWI789644B (zh)	2017-04-20	2023-01-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
EP3521308B1 (fr) *	2018-01-31	2024-03-13	Vivoryon Therapeutics N.V.	Anticorps humanisés et dé-immunisés
WO2019169448A1 (fr) *	2018-03-09	2019-09-12	St Vincent's Institute Of Medical Research	Anticorps multi-spécifiques
WO2020023530A2 (fr) *	2018-07-24	2020-01-30	Eisai R&D Management Co., Ltd.	Méthodes de traitement et de prévention de la maladie d'alzheimer
CN111184725B (zh) *	2020-02-27	2020-12-01	慈溪市人民医院医疗健康集团(慈溪市人民医院)	一种防治脑梗塞的药物制剂及其制备方法
PE20231507A1 (es) *	2020-10-02	2023-09-26	Lilly Co Eli	Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
CN116916957A (zh) *	2021-01-11	2023-10-20	伊莱利利公司	抗N3pGlu淀粉样蛋白β抗体及其用途
TWI843040B (zh) *	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) *	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (fr)	2021-05-24	2022-12-01	Eli Lilly And Company	Anticorps anti-amyloïde bêta et leurs utilisations
US20260125460A1 (en) *	2021-10-29	2026-05-07	Eli Lilly And Company	Compounds and methods targeting interleukin-34
CA3236560A1 (fr) *	2021-10-29	2023-05-04	Marcio Chedid	Composes et procedes ciblant l'interleukine-34
MX2024005144A (es) *	2021-10-29	2024-05-13	Lilly Co Eli	Compuestos y metodos dirigidos a la interleucina-34.
IL312380A (en) *	2021-10-29	2024-06-01	Lilly Co Eli	Compounds and methods targeting interleukin-34
KR102753583B1 (ko) *	2021-11-11	2025-01-10	의료법인 명지의료재단	Kras 특이적 활성화 t 세포 유도용 항원 조성물
WO2023146818A2 (fr) *	2022-01-26	2023-08-03	T3D Therapeutics, Inc.	Procédés de traitement de troubles cérébraux liés à l'amyloïde à l'aide de nouveaux composés et d'anticorps
CA3243602A1 (fr) *	2022-02-03	2023-08-10	Eli Lilly And Company	Imagerie de tau régionale pour le diagnostic et le traitement de la maladie d'alzheimer
IL328051A (en)	2023-11-14	2026-06-01	Lilly Co Eli	Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1397539A (en) *	1920-01-14	1921-11-22	Odell Risdon Moore	Egg-carton
EA006606B1 (ru)	2000-02-24	2006-02-24	Вашингтон Юниверсити	Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
US7122374B1 (en)	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (fr)	2002-07-24	2004-02-12	Innogenetics N.V.	Prevention, traitement et diagnostic de maladies associees a la formation et/ou a l'agregation de la beta-amyloide
CA2538220A1 (fr)	2003-09-09	2005-03-24	Takeda Pharmaceutical Company Limited	Utilisation d'un anticorps
AU2005290250A1 (en)	2004-07-30	2006-04-06	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
CA2632828C (fr)	2005-12-12	2012-07-10	F. Hoffmann-La Roche Ag	Anticorps contre la beta-amyloide ayant subi une glycosylation dans la region variable
MY169492A (en)	2006-03-23	2019-04-15	Bioarctic Neuroscience Ab	Improved protofibril selective antibodies and the use thereof
RU2498999C2 (ru)	2006-07-14	2013-11-20	Ац Иммуне Са	Гуманизированное антитело к амилоиду бета
WO2008088983A1 (fr)	2007-01-18	2008-07-24	Eli Lilly And Company	Aβ pégylé-fab
ES2498040T3 (es) *	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
CA2723995A1 (fr)	2008-06-12	2009-12-17	Affiris Ag	Composes destines au traitement de symptomes associes a la maladie de parkinson
WO2010004434A2 (fr)	2008-07-09	2010-01-14	University Of Zurich	Procédé d'activation de la neurogenèse
KR101706789B1 (ko)	2008-07-21	2017-02-14	프로비오드룩 아게	진단용 항체 검사법
CN101397539B (zh) *	2008-10-14	2011-10-05	中国人民解放军第三军医大学	组织工程组织仿生培养的模拟人体生理应力的施力装置
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8795664B2 (en)	2010-06-04	2014-08-05	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Monoclonal antibodies targeting amyloid beta oligomers
SI3339323T1 (sl) *	2010-08-12	2019-12-31	Eli Lilly And Company	Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
WO2012021475A2 (fr)	2010-08-12	2012-02-16	Eli Lilly And Company	ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
WO2012136552A1 (fr)	2011-04-08	2012-10-11	H. Lundbeck A/S	Anticorps spécifiquement dirigés contre la protéine bêta-amyloïde pyroglutamatée
EP2928494A4 (fr)	2012-12-07	2016-11-02	Biogen Internat Neuroscience Gmbh	Procédé de réduction des plaques amyloïdes cérébrales au moyen d'anticorps anti-ass
TWI593692B (zh)	2013-03-12	2017-08-01	美國禮來大藥廠	四氫吡咯并噻嗪化合物
TW202239429A (zh)	2014-02-08	2022-10-16	美商建南德克公司	治療阿茲海默症之方法
WO2015175769A1 (fr) *	2014-05-15	2015-11-19	Biogen Ma Inc.	Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
WO2015191825A1 (fr) *	2014-06-13	2015-12-17	Biogen Ma Inc.	Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques
JP6201928B2 (ja) *	2014-08-04	2017-09-27	トヨタ自動車株式会社	車両制御装置
TWI570127B (zh)	2014-09-15	2017-02-11	美國禮來大藥廠	結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) *	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
WO2016053767A1 (fr)	2014-09-30	2016-04-07	Merck Sharp & Dohme Corp.	Nouvelles formes cristallines d'un inhibiteur de bace, compositions, et utilisation associées
MA41115A (fr) *	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
JOP20170004B1 (ar)	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途

2017
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/fr active Active
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/fr active Pending
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 DK DK17736841.2T patent/DK3478712T5/da active
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 IL IL263788A patent/IL263788B2/en unknown
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/fr not_active Ceased
- 2017-06-23 UA UAA202202998A patent/UA129392C2/uk unknown
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 NZ NZ772768A patent/NZ772768A/en unknown
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Withdrawn
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active Active
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active Ceased
- 2017-06-23 CA CA3029550A patent/CA3029550C/fr active Active
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
2020
- 2020-12-03 JP JP2020201051A patent/JP7884323B2/ja active Active
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US11312763B2 (en)	2022-04-26
AU2017291414A1 (en)	2018-12-13
TW201811363A (zh)	2018-04-01
IL263788A (en)	2019-01-31
EP3478712A1 (fr)	2019-05-08
JP7884323B2 (ja)	2026-07-03
CN114887054A (zh)	2022-08-12
PL3478712T3 (pl)	2023-11-06
MX2018016066A (es)	2019-04-24
RS64386B1 (sr)	2023-08-31
DK3478712T3 (da)	2023-09-04
JP2021059546A (ja)	2021-04-15
LT3478712T (lt)	2023-08-25
KR20190012208A (ko)	2019-02-08
CN109415433A (zh)	2019-03-01
FI3478712T3 (fi)	2023-10-02
ES2958508T3 (es)	2024-02-09
CN114917338A (zh)	2022-08-19
UA129392C2 (uk)	2025-04-09
MD3478712T2 (ro)	2024-01-31
CA3029550C (fr)	2023-08-22
JP2023123503A (ja)	2023-09-05
WO2018005282A1 (fr)	2018-01-04
EP3478712B1 (fr)	2023-07-19
JP7165588B2 (ja)	2022-11-04
KR102221402B1 (ko)	2021-03-02
CA3029550A1 (fr)	2018-01-04
MA45543B1 (fr)	2023-08-31
IL263788B2 (en)	2024-10-01
KR20210024213A (ko)	2021-03-04
EP4272828A2 (fr)	2023-11-08
AU2017291414B2 (en)	2019-11-21
IL263788B1 (en)	2024-06-01
EA201892690A1 (ru)	2019-05-31
TWI735600B (zh)	2021-08-11
DK3478712T5 (da)	2024-09-09
TW202140544A (zh)	2021-11-01
UA127101C2 (uk)	2023-04-19
EP4272828A3 (fr)	2024-01-10
TWI798751B (zh)	2023-04-11
JP2021059547A (ja)	2021-04-15
JP2019518783A (ja)	2019-07-04
US20190382471A1 (en)	2019-12-19
SI3478712T1 (sl)	2023-10-30
NZ772768A (en)	2024-11-29
KR20230021773A (ko)	2023-02-14
PT3478712T (pt)	2023-08-21
SG11201810371XA (en)	2018-12-28
JP7241058B2 (ja)	2023-03-16
US20220235122A1 (en)	2022-07-28
BR112018073843A2 (pt)	2019-02-26
NZ748496A (en)	2021-02-26
MX2023001299A (es)	2023-02-22
HRP20230861T1 (hr)	2023-11-10
ZA201807633B (en)	2021-05-26
HUE062980T2 (hu)	2023-12-28

Publication	Publication Date	Title
EP3626825A4 (fr)	2021-02-17	Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3762030A4 (fr)	2022-01-05	Anticorps anti-cd73 et utilisations associées
MA50144A (fr)	2020-07-29	Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
EP3658589C0 (fr)	2023-09-27	Anticorps anti-sirp-alpha et méthodes associées
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA46525A (fr)	2019-08-21	Anticorps anti-lag-3 et compositions
IL256271B (en)	2022-01-01	Anti-cd123 antibodies and conjugates and derivatives thereof
EP3400243A4 (fr)	2019-09-25	Anticorps anti-pd-l1 et utilisations associées
EP3504243A4 (fr)	2020-03-11	Anticorps anti-tim-3 et leurs utilisations
EP3473649A4 (fr)	2020-06-17	Anticorps monoclonal anti-cd47 et application correspondante
MA44659A (fr)	2021-04-14	Anticorps anti-tim-3 et compositions
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3735427A4 (fr)	2021-09-15	Anticorps anti-mct1 et utilisations associées
EP3397276A4 (fr)	2019-12-18	Anticorps et conjugués de ceux-ci
EP3307274A4 (fr)	2019-02-27	Anticorps anti-cd123 et conjugués de ceux-ci
EP3733702A4 (fr)	2021-09-29	Anticorps anti-lag-3 et utilisations associées
EP3283517A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA45233A (fr)	2019-04-17	Anticorps anti-gitr et leurs utilisations